NEW YORK (GenomeWeb News) – Luminex and the Tecan Group today announced a collaboration to develop new automated screening platform for the faster detection of potential health risks in newborns.
The global original equipment manufacturing agreement will combine Luminex's xMAP technology and LX200 instrument with Tecan's Freedom EVO liquid handling platform and HydroFlex Washer.
Terms of the deal were not announced.
In a joint statement, Luminex said that it expects to launch the platform, to be called NeoPlex4, in 2011 and "once it receives regulatory clearance, [it] will be a fully automated, walk-away testing platform for multiplexed newborn screening." The platform, it added, will increase laboratory efficiency, save "vital resources," and allow researchers to analyze more samples more quickly.
NeoPlex4 will test newborn infants for several different biomarkers linked to critical diseases. The firms did not identify the diseases but said that they can cause "severe" mental and physical disability if untreated. "Multiplexing these test together from one sample offers significant improvements in testing efficiency," they said.